Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

SK hynix Weighs Kioxia Bond Conversion

SK hynix is considering a plan to convert the convertible bonds it secured through its investment in the Japanese NAND flash manufacturer Kioxia into shares.According to the industry on Nov. 20, SK hynix is reviewing the conversion into shares of the convertible bonds secured during its investment p

SK hynix is contemplating a strategy to transform the convertible bonds acquired through its investment in Japanese NAND flash manufacturer Kioxia into common shares. According to industry reports on November 20, SK hynix is evaluating the conversion of these convertible bonds, which were obtained during its investment process with Kioxia, into shares.

SK hynix had invested in Kioxia through the U.S. private equity firm Bain Capital, purchasing a 395 billion yen stake equivalent to approximately $2.92 billion at the time. This investment was in the form of both funds and convertible bonds. The equity fund that received 2.6 trillion won (around $1.95 billion) of the investment amount was fully sold off in June.

Following this sale, SK hynix decided to distribute the capital gains obtained as special dividends to shareholders beginning with the third quarter of the current year. The remaining investment asset after the sale is the convertible bond issued by a special purpose company (SPC2). SPC2, established to hold a stake in Kioxia, is currently the largest shareholder with a 14.53% stake in the company as of the end of September.

If SK hynix opts to convert the convertible bond into shares, it would gain control of the majority of SPC2's voting rights, effectively becoming the company’s indirect largest shareholder. SK hynix has not expressed any intention to sell its shares immediately, should the bond conversion occur. Consequently, the company believes its stake in Kioxia would remain unchanged, even after the bonds are converted into shares.

SK hynix has stated its commitment to cooperate with Kioxia’s independent management, regardless of the bond conversion decision.

Written by urgent.news from BusinessKorea's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at businesskorea.co.kr →

More in Finance & Markets

Moderna vs. BioNTech: Why Only 1 Is a Buy Heading Into 2027

One of these mRNA pioneers has the products and pipeline to drive growth.

  • Moderna and BioNTech transitioned beyond coronavirus vaccines in 2026
  • BioNTech's future depends on CEO and CMO leadership transition by Feb 1
  • Moderna has commercialized flu vaccine and advancing intismeran in oncology

More from Friday 20 November →